2017
DOI: 10.1002/14651858.cd011305.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background-Many people diagnosed with haematological malignancies experience anaemia, and red blood cell (RBC) transfusion plays an essential supportive role in their management.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

3
38
0
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 36 publications
(42 citation statements)
references
References 64 publications
3
38
0
1
Order By: Relevance
“…As an example, data in medical records on haemoglobin values and transfusion indications were not complete. Platelet values at the time of RBC transfusion were not recorded, but these have been reported to impact transfusion triggers . DAT results were recorded for a subset of patients and were not analysed further in this paper.…”
Section: Discussionmentioning
confidence: 99%
“…As an example, data in medical records on haemoglobin values and transfusion indications were not complete. Platelet values at the time of RBC transfusion were not recorded, but these have been reported to impact transfusion triggers . DAT results were recorded for a subset of patients and were not analysed further in this paper.…”
Section: Discussionmentioning
confidence: 99%
“…As a result, critically ill OH patients can be exposed to a large volume of RBC. The optimal transfusion strategy remains undefined in this setting . A recent single centre RCT attempted to compare the outcomes in OH septic shock patients transfused according to two different Hb thresholds (7 or 9 g/dl) during their ICU stay .…”
Section: When To Transfuse Critically Ill Patients?mentioning
confidence: 99%
“…Infanti et al show that in routine use, 61.6-77.6% (mean 75.8%) of conventional PC and 58.2-75.2% (mean 64.6%) of amotosalen/UVA treated PR-PC (INTERCEPT Blood System, Cerus Corp.) achieved CCI's ≥ 5,000 in various patient populations. 1 These data imply that by chance alone, ([1.0-0.758] 2 = 0.059) 5.9% of consecutive conventional and ([1.0-0.646] 2 = 0.125) 12.5% of consecutive INTERCEPT PC transfusions will meet the definition of clinical refractoriness. Alloimmunization to HLA class I or platelet specific antigens (e.g., PLA1) is a relatively infrequent cause but may be associated with life-threatening resistance to PC therapy and an increased risk of hemorrhagic death.…”
mentioning
confidence: 97%
“…Only very limited data is available on the optimal transfusion trigger in this setting. 1 The Temple (Transfusion Effects in Myelodysplastic Patients: Limiting Exposure) Study was a multicenter, randomized, non-inferiority clinical trial that compared a restrictive (Hb transfusion trigger <4.5 mmoL/L, <7.3 g/dL) with a standard (liberal) transfusion policy (Hb transfusion trigger <6.0 mmoL/L, <9.7 g/dL) in patients with MDS. Primary endpoint was physical fatigue, measured with the Multidimensional Fatigue Inventory (MFI).…”
mentioning
confidence: 99%
See 1 more Smart Citation